DGAP-News: Proteo, Inc./ Proteo Biotech AG: Proteo's Elafin will be tested at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)
(firmenpresse) - Proteo Biotech AG / Agreement/Alliance
18.06.2010 09:50
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Proteo, Inc. / Proteo Biotech AG: Proteo's Elafin will be tested at the
U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).
Irvine, CA, June 18, 2010 - Proteo, Inc. (OTCBB:PTEO; Frankfurter
Freiverkehr: WKN: 925981) and its wholly-owned subsidiary Proteo Biotech AG
announced today the signing of a cooperative research and development
agreement with the U.S. Army Medical Research Institute of Infectious
Diseases (USAMRIID). Under the agreement Proteo will provide USAMRIID with
Elafin and related scientific data in order to plan and
conduct preclinical research on the development of new therapeutic
strategies to combat life-threatening infectious diseases.
Scientists from the U.S. Army Medical Research Institute of Infectious
Diseases are investigating therapies to treat individuals that have become
symptomatic after exposure to one of the bacterial bio-threat agents
(anthrax, plague, tularemia, glanders or melioidosis). One direction their
research has taken is to attempt to mitigate or alter the immunological
response that in many cases is the ultimate cause of death in these
infections. They are interested in investigating if Proteo's Elafin could
help as a co-therapy with antibiotics.
Proteo's CEO, Birge Bargmann:»We are looking forward to the results of the
U.S. Army Medical Research Institute of Infectious Diseases regarding the
use of our Lead Product, Elafin, in preclinical models«.
Further information on the clinical development program for Elafin:
Proteo's drug substance Elafin is a natural human antagonist of elastase
and proteinase-3, two potent tissue destroying enzymes, both of which
participate in the inflammatory mechanism of a variety of diseases.
Elafin's ability to block these inflammation promoting enzymes makes it a
promising drug candidate for the treatment of inflammatory lung diseases
and severe reperfusion injury. The excellent tolerability of intravenously
administered recombinant Elafin was demonstrated convincingly in a Phase I
clinical trial. The results of a Phase II clinical trial for the treatment
of postoperative inflammatory reactions of esophagus carcinoma are
currently being evaluated. Proteo's licensing and development partner,
Minapharm Pharmaceuticals SAE, has initiated a further Phase II clinical
trial on the use of Elafin in kidney transplantation patients. This trial
is concerned with the prevention of acute organ rejection and chronic graft
injury (allograft nephropathy) and will be conducted at the University of
Cairo. As a further cooperation partner, the University of Edinburgh is
planning a clinical trial to test Elafin in the context of bypass surgery
after a heart attack.
About Proteo:
The company researches, develops and markets compounds for biological and
medical research as well as for use as pharmaceuticals. The main focus is
on anti-inflammatory drugs, in particular on the human elastase inhibitor
Elafin. Proteo intends to out-license selected indications and to establish
international strategic alliances inorder to open up new fields of
application and for marketing (www.proteo.us).
About USAMRIID:
USAMRIID, located at Fort Detrick, Maryland, is the lead medical research
laboratory for the U.S. Department of Defense's Biological Defense Research
Program, and plays a key role in national defense and in infectious disease
research. The Institute conducts basic and applied research on biological
threats resulting in medical solutions (such as vaccines, drugs and
diagnostics) to protect the warfighter. While USAMRIID's primary mission is
focused on the military, its research often has applications that benefit
society as a whole. USAMRIID is a subordinate laboratory of the U.S. Army
Medical Research and Materiel Command. For more information, visit
www.usamriid.army.mil.
The information contained in this press release does not necessarily
reflect the position or the policy of the Government and no official
endorsement should be inferred.
Forward-Looking Statements:
Certain statements in this news release may contain forward-looking
information within the meaning of Rule 175 under the Securities Act of 1933
and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to
the safe harbor created by those rules. All statements, other than
statements of fact included in this release, including, without limitation,
statements regarding potential future plans and objectives of the company,
are forward-looking statements that involve risks and uncertainties. There
can be no assurance that such statements will prove to be accurate and
actual results and future events could differ materially from those
anticipated in such statements. Technical complications that may arise
could prevent the prompt implementation of any strategically significant
plan(s) outlined above. The company cautions that these forward looking
statements and risks and uncertainties involved are further qualified by
other factors including, but not limited to those set forth in the
company's Form 10-K filing and other filings with the United States
Securities and Exchange Commission. The company undertakes no obligation to
publicly update or revise any statements in this release, whether as a
result of new information, future events or otherwise.
Contact:
Dr. Barbara Kahlke
Proteo Biotech AG
Am Kiel-Kanal 44
D-24106 Kiel
Email: info(at)proteo.us
Phone: +49(0)431 8888462
Fax : +49(0)431 8888463
18.06.2010 09:50 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Medienarchiv atwww.dgap-medientreff.deandwww.dgap.de---------------------------------------------------------------------------
Bereitgestellt von Benutzer: EquityStory
" alt="CROWFLIGHT ANNOUNCES MAY PRODUCTION RESULTS
Datum: 18.06.2010 - 09:50 Uhr
Sprache: Deutsch
News-ID 22649
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 257 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Proteo, Inc./ Proteo Biotech AG: Proteo's Elafin will be tested at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)"
steht unter der journalistisch-redaktionellen Verantwortung von
Proteo Biotech AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
